Amyris, Inc. (AMRSQ)
- Previous Close
0.0015 - Open
0.0010 - Bid --
- Ask --
- Day's Range
0.0010 - 0.0015 - 52 Week Range
0.0000 - 0.1634 - Volume
28,002 - Avg. Volume
312,883 - Market Cap (intraday)
372,324 - Beta (5Y Monthly) 5.03
- PE Ratio (TTM)
-- - EPS (TTM)
-1.8500 - Earnings Date Apr 29, 2024 - May 7, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Amyris, Inc. operates as a biotechnology company in Europe, North America, Asia, South America, and internationally. It creates, manufactures, and commercializes consumer products and ingredient, including clean beauty, personal care, and health and wellness consumer products; and ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets. The company markets its products under the Biossance, JVN, Rose Inc., Pipette, Costa Brazil, OLIKA, Purecane, Terasana, MenoLabs, EcoFabulous, Stripes, and 4U by Tia brand names. It has a collaboration and license agreement with the Infectious Disease Research Institute for the development of a COVID-19 vaccine. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was incorporated in 2003 and is headquartered in Emeryville, California. On August 9, 2023, Amyris, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
amyris.com1,598
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Related News
Performance Overview: AMRSQ
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AMRSQ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AMRSQ
Valuation Measures
Market Cap
372.32k
Enterprise Value
1.02B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.00
Price/Book (mrq)
--
Enterprise Value/Revenue
3.82
Enterprise Value/EBITDA
-1.82
Financial Highlights
Profitability and Income Statement
Profit Margin
-229.12%
Return on Assets (ttm)
-46.40%
Return on Equity (ttm)
--
Revenue (ttm)
268.22M
Net Income Avi to Common (ttm)
-614.55M
Diluted EPS (ttm)
-1.8500
Balance Sheet and Cash Flow
Total Cash (mrq)
11.24M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-312.66M